Highmark Blue Cross Blue Shield to Cover Non-Invasive Esophageal Cancer Screening
NEW YORK, March 13, 2025 – Lucid Diagnostics Inc. (Nasdaq: LUCD) today announced a significant development in cancer prevention. Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has approved a positive coverage policy for non-invasive screening of esophageal precancer and cancer within New York state.
This new policy will cover Lucid’s EsoGuard® Esophageal DNA Test for patients who meet the established criteria for esophageal precancer testing, as outlined by professional society guidelines. This decision marks a pivotal moment for the company.
“This positive policy coverage decision by a commercial insurer is a landmark event for Lucid,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “We believe that this decision will serve as a precedent to drive positive policy coverage decisions from other commercial insurers and further validates the strength of our clinical evidence base. We remain deeply engaged with commercial insurers across the country as we seek to expand access to EsoGuard precancer testing.”
Lucid Diagnostics is dedicated to providing innovative solutions for patients with gastroesophageal reflux disease (GERD), often referred to as chronic heartburn, who face an increased risk of developing esophageal precancer and cancer. The EsoGuard® Esophageal DNA Test, paired with the EsoCheck® Esophageal Cell Collection Device, offers a noninvasive office procedure designed for the early detection of esophageal precancer. Early detection is crucial to preventing esophageal cancer.
For additional information, please visit www.luciddx.com and for information about the parent company, PAVmed, visit www.pavmed.com.
Forward-Looking Statement Disclaimer:
This press release contains forward-looking statements that involve risks and uncertainties. Actual results could differ from these statements due to various factors including, but not limited to, market conditions, research and development uncertainties, regulatory approvals, product acceptance, and the company’s ability to secure additional funding. Lucid Diagnostics is also monitoring the impact of the COVID-19 pandemic on its business operations. For a detailed discussion of these and other risks, please review the “Risk Factors” section in Lucid’s most recent filings with the Securities and Exchange Commission.
